Analysis of the relationship between high blood pressure and coronary artery disease
DOI:
https://doi.org/10.55892/jrg.v8i18.1798Keywords:
Coronary artery disease; Arterial hypertension; Prevention.Abstract
Hypertension (HTN) is an important risk factor for the progression of coronary artery disease (CAD). The relationship between hypertension and CAD involves mechanisms such as increased atherosclerosis, endothelial dysfunction, damage to the heart and vessels, and arterial stiffness, which compromises coronary perfusion. This contribution highlights the need for strict blood pressure control in high-risk patients. Therapeutic strategies include beta-blockers, statins, antiplatelet therapy, and lifestyle changes, enhanced by mobile technologies that aid in monitoring and adherence. Procedures such as coronary bypass are indicated in advanced cases. Integrated management is essential to reduce the overall burden of CAD and improve cardiovascular outcomes. Studies such as SPRINT and STEP demonstrate that stricter blood pressure targets (<120 mmHg) significantly reduce the risk of cardiovascular events in the elderly, while meta-analyses show that each 5 mmHg reduction in SBP reduces cardiovascular events by 10%. Blood pressure control prevents inflammation, endothelial dysfunction, and vascular remodeling, slowing the progression of atherosclerosis. However, economic and social barriers, especially in Latin America, hinder the adequate management of hypertension. Educational campaigns, access to medications, and public policies are crucial to overcoming these challenges, highlighting the need for strategies that integrate clinical control and socioeconomic support to reduce inequalities. Therefore, strict blood pressure control reduces cardiovascular risks, so a combination of pharmacological control, lifestyle changes, and inclusive public policies is necessary to reduce the global burden of cardiovascular diseases.
Downloads
References
Wan, E. Y. F., Yu, E. Y. T., Chin, W. Y., Fong, D. Y. T., Choi, E. P. H., & Lam, C. L. K. (2019). Association of blood pressure and risk of cardiovascular and chronic kidney disease in Hong Kong hypertensive patients. Hypertension, 74(2), 331–340. https://doi.org/10.1161/HYPERTENSIONAHA.119.13123. Acesso em: 25 out. 2024.
Parra-Gómez, L. A., Galeano, L., Chacón-Manosalva, M., & Camacho, P. (2023). Barreras para el conocimiento, el tratamiento y el control de la hipertensión arterial en América Latina: una revisión de alcance. Revista panamericana de salud publica [Pan American journal of public health], 47, e26. https://doi.org/10.26633/RPSP.2023.26. Acesso em: 25 out. 2024.
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., ... ESC Scientific Document Group. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484. Acesso em: 25 out. 2024.
Marques-Vidal, P. (2023). High blood pressure puts a high pressure in low- and middle-income countries. European journal of preventive cardiology, 30(10), 916. https://doi.org/10.1093/eurjpc/zwac207.
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. M., ... Nadruz, W. (2021). Brazilian Guidelines of Hypertension - 2020. Arquivos brasileiros de cardiologia, 116(3), 516–658. https://doi.org/10.36660/abc.20201238. Acesso em: 25 out. 2024.
Zeinali-Nezhad, N., Najafipour, H., Shadkam, M., & Pourhamidi, R. (2024). Prevalence and trend of multiple coronary artery disease risk factors and their 5-year incidence rate among adult population of Kerman: results from KERCADR study. BMC Public Health, 24(1), 25. https://doi.org/10.1186/s12889-023-17504-8. Acesso em: 25 out. 2024.
Volpe, M., & Gallo, G. (2023). Hypertension, coronary artery disease and myocardial ischemic syndromes. Vascular Pharmacology, 153, 107230. https://doi.org/10.1016/j.vph.2023.107230. Acesso em: 25 out. 2024.
Duggan, J. P., Peters, A. S., Trachiotis, G. D., & Antevil, J. L. (2022). Epidemiology of coronary artery disease. The Surgical Clinics of North America, 102(3), 499–516. https://doi.org/10.1016/j.suc.2022.01.007. Acesso em: 25 out. 2024.
Carey, R. M., Wright, J. T., Jr, Taler, S. J., & Whelton, P. K. (2021). Guideline-Driven Management of Hypertension: An Evidence-Based Update. Circulation Research, 128(7), 827–846. https://doi.org/10.1161/CIRCRESAHA.121.318083. Acesso em: 22 dez. 2024.
Volpe, M., & Gallo, G. (2023). Hypertension, coronary artery disease and myocardial ischemic syndromes. Vascular Pharmacology, 153, 107230. https://doi.org/10.1016/j.vph.2023.107230. Acesso em: 31 out. 2024.
Sigamani, A., & Gupta, R. (2022). Revisiting secondary prevention in coronary heart disease. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36455667/. Acesso em: 25 out. 2024.
Prasad, K. (2021). Current Status of Primary, Secondary, and Tertiary Prevention of Coronary Artery Disease. International Journal of Angiology, 30(3), 177–186. https://doi.org/10.1055/s-0041-1731273. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34776817/. Acesso em: 30 out. 2024.
Gray, H., Indraratna, P., Lovel, N., & Ooi, S.-Y. (2022). Digital health technology in the prevention of heart failure and coronary artery disease. Journal of Cardiovascular Disease Prevention, 3(6), S9–S16. Disponível em: https://www.sciencedirect.com/science/article/pii/S2666693622001542. Acesso em: 31 out. 2024.
Lucca, M. B., Fuchs, F. C., Almeida, A. S., Wainstein, M. V., Fuchs, F. D., & Fuchs, S. C. (2023). Prevenção farmacológica secundária da doença arterial coronariana em pacientes submetidos ao manejo clínico, intervenção coronária percutânea ou cirurgia de revascularização miocárdica. Arquivos Brasileiros de Cardiologia. https://doi.org/10.36660/abc.20220403. Disponível em: https://www.scielo.br/j/abc/a/d7BK3PRW7yjjT3QMtrXjhJP/?lang=pt. Acesso em: 31 out. 2024.
Fuchs, F. D., & Whelton, P. K. (2020). High Blood Pressure and Cardiovascular Disease. American Heart Association, 75(2), 285–292. https://doi.org/10.1161/HYPERTENSIONAHA.119.14240.
Chen, T., Shao, F., Chen, K., Wang, Y., Wu, Z., Wang, Y., ... Jiang, Z. (2022). Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension: A Secondary Analysis of Randomized Clinical Trials. JAMA Intern Med, 182(6), 660–667. https://doi.org/10.1001/jamainternmed.2022.1657.
Zhang, W., Zhang, S., Deng, Y., et al. (2021). Trial of intensive blood-pressure control in older patients with hypertension. New England Journal of Medicine, 385(14), 1268–1279. https://doi.org/10.1056/NEJMoa2111437.
Lewis, C. E., Fine, L. J., Beddhu, S., et al. (2021). Final report of a trial of intensive versus standard blood-pressure control. New England Journal of Medicine, 384(20), 1921–1930. https://doi.org/10.1056/NEJMoa1901281.
The Blood Pressure Lowering Treatment Trialists’ Collaboration. (2021). Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet, 397, 1625–1636. https://doi.org/10.1016/S0140-6736(21)00590-0.
Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., ... Mancia, G. (2024). Diretrizes de prática clínica da Sociedade Europeia de Hipertensão de 2024 para o tratamento da hipertensão arterial. Jornal Europeu de Medicina Interna, 126, 1–15. https://doi.org/10.1016/j.ejim.2024.05.033.